Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT02299999 2025-01-15

SAFIR02_Breast

Phase 2 Active not recruiting

1,460 enrolled

Breast

Breast Neoplasms

NCT06731153 2024-12-12

JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC

Phase 2 Not yet recruiting

40 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06102824 2024-11-25

ORIENTA

Phase 2 Recruiting

252 enrolled

Breast

HER2-negative Breast Cancer

NCT06678230 2024-11-07

Clinical Trial of Eribulin in Combination with Anrotinib for HER-2 Negative Locally Advanced or Metastatic Breast Cancer

Phase 2 Unknown

40 enrolled

Breast

Breast Neoplasms

NCT01827787 2024-11-06

Eribulin in HER2 Negative Metastatic BrCa

Phase 2 Completed

83 enrolled 18 charts

Breast

Breast Neoplasms

NCT02681523 2024-09-19

ALERT

Phase 2 Terminated

8 enrolled 20 charts

Breast

Breast Neoplasms

NCT02037529 2024-08-20

Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer

Phase 3 Suspended

201 enrolled 19 charts

Breast

Breast Neoplasms

NCT06539559 2024-08-06

Efficacy and Resistant Mechanism of Eribulin and Bevacizumab for Advanced HER2 Negative Breast Cancer

Phase 2 Not yet recruiting

60 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT06387628 2024-08-02

LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer

Phase 2 Recruiting

74 enrolled

Breast

Triple Negative Breast Neoplasms

NCT04464174 2024-07-26

PATHFINDER

Phase 2 Completed

54 enrolled

Breast

Triple Negative Breast Neoplasms

NCT03393741 2024-06-25

Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy

Terminated

5 enrolled

Breast

Breast Neoplasms

NCT02035813 2024-06-04

DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).

Phase 2 Completed

116 enrolled

Breast

Breast Neoplasms, Neoplastic Cells, Circulating

NCT02344472 2024-06-04

Detect V / CHEVENDO (Chemo vs. Endo)

Phase 3 Active not recruiting

271 enrolled

Breast

Breast Neoplasms

NCT02640508 2024-05-09

Eribulin and Lenvatinib in Advanced Solid Tumors

Phase 2 Completed

29 enrolled 13 charts

Tumor-Agnostic

Neoplasms

NCT02338037 2024-03-19

Neuropharmacokinetics of Eribulin Mesylate in Treating Patients With Primary or Metastatic Brain Tumors

Phase EARLY_PHASE1 Completed

8 enrolled

CNS

Brain Neoplasms

NCT06308939 2024-03-13

Eribulin Combined With Sintilimab as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Breast Cancer:A Multicenter, Single-arm,Phase II Clinical Trial

Phase 2 Not yet recruiting

81 enrolled

Breast

Breast Neoplasms

NCT03051659 2024-03-06

A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer

Phase 2 Completed

90 enrolled 13 charts

Breast

Breast Neoplasms

NCT06268652 2024-02-20

Patient Derived Organoid-guided Personalized Treatment Versus Treatment of Physician's Choice in Breast Cancer

Phase 3 Recruiting

302 enrolled

Breast

Breast Neoplasms

Clinical Trials

MBC-EA

Eribulin and Radiation Therapy in Treating Patients With Retroperitoneal Liposarcoma That Can Be Removed by Surgery

JAZMINE

The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis

SABINA

A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer Harboring a PIK3CA Mutation

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

NETHER

Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)

SOLARA

Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer

Adaptive Chemotherapy for the Treatment of Advanced Breast Cancer

LEADER

Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negative Breast Cancer)

A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer

ESPERO

Scalp Cooling in MBC

A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors

Eribulin Mesylate in Treating Patients With Advanced or Recurrent Cervical Cancer

A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer

Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma

A Multicenter, Single-arm, Prospective Phase II Clinical Study of Epalrotokewali Combined With Eribulin, Anlotinib, and Radiotherapy for the Treatment of Patients With Advanced Soft Tissue Sarcoma.

EMERALD

PRECIOUS

ALPHABET

A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas

Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer

Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer

Adaptive Therapy for Post-Second-Line Advanced Breast Cancer

MERIBEL

KELLY

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

SAFIR02_Breast

JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC

ORIENTA

Clinical Trial of Eribulin in Combination with Anrotinib for HER-2 Negative Locally Advanced or Metastatic Breast Cancer

Eribulin in HER2 Negative Metastatic BrCa

ALERT

Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer

Efficacy and Resistant Mechanism of Eribulin and Bevacizumab for Advanced HER2 Negative Breast Cancer

LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer

PATHFINDER

Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy

DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).

Detect V / CHEVENDO (Chemo vs. Endo)

Eribulin and Lenvatinib in Advanced Solid Tumors

Neuropharmacokinetics of Eribulin Mesylate in Treating Patients With Primary or Metastatic Brain Tumors

Eribulin Combined With Sintilimab as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Breast Cancer:A Multicenter, Single-arm,Phase II Clinical Trial

A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer

Patient Derived Organoid-guided Personalized Treatment Versus Treatment of Physician's Choice in Breast Cancer